UBS has maintained a buy rating on London Stock Exchange Group (LSEG) shares, citing a sharp 13% drop that pushed the stock's valuation to a 14-year low. The Swiss bank sees about 35% upside, with a price target of 11,700p, and expects annual earnings growth of 14-15% through 2028. UBS highlights that the market undervalues LSEG's data and analytics division, pricing it below £1 billion, despite potential AI disruption risks being limited to part of the business. The bank anticipates revenue growth from LSEG's MCP server, which connects AI models to its data, with wider adoption expected in early 2027, potentially boosting investor confidence.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
